GCA and aPL
| All GCA | aPL | aCL | aB2GPI | aPS/PT e | LA | |
|---|---|---|---|---|---|---|
| positive | positive | positive | positive | |||
| Number of cases | 121 | 28 | 55 | 15 | 18 | 59 |
| Female (%) | 66.9 | 67.9 | 72.7 | 60.0 | 66.7 | 66.1 |
| General symptoms (%) | 76.0 | 67.9 | 78.2 | 66.7 | 66.7 | 81.4 |
| Headache (%) | 69.4 | 82.1 | 61.8 | 66.7 | 61.1 | 71.2 |
| Jaw claudication (%) | 42.1 | 46.4 | 43.6 | 33.3 | 22.2 | 44.1 |
| Visual symptoms (%) | 24.0 | 35.7 | 20.0 | 13.3 | 22.2 | 16.9 |
| PVL or TVL (%) | 12.4 | 14.3 | 16.4 | 13.3 | 5.6 | 11.9 |
| PMR (%) | 14.0 | 14.3 | 16.4 | 6.7 | 22.2 | 11.9 |
| Stroke (%) | 2.5 | 3.6 | 3.6 | 0 | 0 | 0 |
| Venous thrombosis (%) | 0.8 | 3.6 | 0 | 0 | 0 | 0 |
| LVV (CDS) (%) | 38.8 | 38.5 | 50.9 | 33.3 | 17.6 | 31.0 |
| TA CDS (%) | 80.2 | 78.6 | 74.5 | 80.0 | 88.9 | 79.7 |
| TAB (%) | 83.0 | 86.4 | 92.5 | 76.9 | 84.6 | 76.6 |
| ESR (mm/h)# | 86 | 75 | 83 | 108 | 88 | 94 |
| (65; 110) | (61; 95) | (64; 107) | (94; 115) | (71; 118) | (73; 116) | |
| CRP (mg/l)# | 73 | 62 | 69 | 95 | 65 | 113 |
| (45; 134) | (36; 124) | (44; 106) | (66; 164) | (52; 117) | (65; 170) | |
| Relapse during follow up (%) | 43.8 | 47.1 | 38.2 | 62.5 | 30.0 | 45.5 |
Legend: aPL antiphospholipid antibodies; TVL transient visual loss (amaurosis fugax); PVL permanent visual loss; TA temporal artery; TAB temporal artery biopsy; CDS color Doppler sonography; LVV large vessel vasculitis; ESR erythrocyte sedimentation rate; CRP C-reactive protein; #median (IQR).